How did AQST's revenue and expenses shift in Q4 2024 compared to previous quarters?
5/8/2025 09:14pm
Aquestive Therapeutics (AQST) exhibited a significant increase in revenue in Q4 2024, with total revenues reaching $57.56 million compared to $12.05 million in Q3 2024, $32.15 million in Q2 2024, and $45.69 million in Q1 2024. However, the company's expenses were not provided for Q4 2024, making it difficult to assess any changes in expenses compared to previous quarters.